REG - LungLife AI, INC - Notice of Results

LungLife AIAnnouncement

03/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230803:nRSC1156Ia&default-theme=true

RNS Number : 1156I  LungLife AI, INC  03 August 2023

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Notice of Results

Investor Presentation

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the
early detection of lung cancer, will announce its unaudited half-year report
for the six months ended 30 June 2023 on Tuesday 8 August 2023.

 

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial
Officer, will be hosting a live online presentation relating to the half-year
report via the Investor Meet Company platform at 4.30pm (BST) on Tuesday 8
August 2023.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here
(https://www.investormeetcompany.com/lunglife-ai-inc/register-investor) .
Investors who already follow LungLife on the Investor Meet Company platform
will automatically be invited.

 

A recording of the presentation and a PDF of the slides used will also be
available on the LungLife website: https://investors.lunglifeai.com/media/
(https://investors.lunglifeai.com/media/)

 

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                                   Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

 Tom Nicholson / Stephen Kane

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                           (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage          Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSSFFIEEDSEDA